Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.5.1.3 (
dihydrofolate reductase
)
5,819
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A non-covalent interaction force field model derived from the partition coefficient of 1-octanol/water solubility is described. This model,
HINT
for Hydropathic INTeractions, is shown to include, in very empirical and approximate terms, all components of biomolecular associations, including hydrogen bonding, Coulombic interactions, hydrophobic interactions, entropy and solvation/desolvation. Particular emphasis is placed on: (1) demonstrating the relationship between the total empirical
HINT
score and free energy of association, deltaGinteraction; (2) showing that the
HINT
hydrophobic-polar interaction sub-score represents the energy cost of desolvation upon binding for interacting biomolecules; and (3) a new methodology for treating constrained water molecules as discrete independent small ligands. An example calculation is reported for
dihydrofolate reductase
(
DHFR
) bound with methotrexate (MTX). In that case the observed very tight binding, deltaGinteraction < or = -13.6 kcal mol(-1), is largely due to ten hydrogen bonds between the ligand and enzyme with estimated strength ranging between -0.4 and -2.3 kcal mol(-1). Four water molecules bridging between
DHFR
and MTX contribute an additional -1.7 kcal mol(-1) stability to the complex. The
HINT
estimate of the cost of desolvation is +13.9 kcal mol(-1).
...
PMID:Very empirical treatment of solvation and entropy: a force field derived from log Po/w. 1134 19
Continued exploration into the field of chemically induced dimerization (CID) has revealed a number of applications for its use in a broader context as a method of structural assembly (1-4). In particular, the use of CID technology to generate self-assembled (and selectively disassembled) protein toroids serves as a key advancement toward developing stable and controllable protein-based platforms. Such structures have broad application to the development of novel therapeutics, lab-on-a-chip technologies, and multi-enzyme assemblies (5, 6). This chapter describes a method of developing an enzymatically active protein nanostructure incorporating both a CID-based assembly region containing
dihydrofolate reductase
(
DHFR
) and an enzymatic region consisting of
histidine triad nucleotide binding protein 1
(Hint1). Details of both the production and the characterization of this structure are provided.
...
PMID:Chemically induced self-assembly of enzyme nanorings. 2155 79